NCT05907759View on ClinicalTrials.gov

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

August 1, 2034

Study Completion Date

December 1, 2035

Conditions
Lymphoma, Primary Effusion
Interventions
DRUG

Daratumumab SC

Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH